Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations analyze observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://charlesx531fhk4.kylieblog.com/profile